Quoted from the $EAPH website: "We believe that the products we are developing will be classified as cosmetics or Class I medical devices. Products classified as cosmetics may be marketed and sold in the US without FDA approval. Drugs are not cosmetics and those, as well as OTC drugs, must be marketed following FDA regulations and/or approvals in the United States. Before human testing can begin with respect to a new drug in the United States, preclinical studies are conducted in laboratory animals to evaluate the potential efficacy and the safety of a product. Human clinical studies generally involve a three-phase process. The initial clinical evaluation, Phase I, consists of administering the product and testing for safe and tolerable dosage levels. Phase II trials continue the evaluation of safety and determine the appropriate dosage for the product, identify possible side effects and risks in a larger group of subjects, and provide preliminary indications of efficacy. Phase III trials consist of testing for actual clinical efficacy within an expanded group of patients at geographically dispersed test sites."
Quoted from the $EAPH website: "We believe that the
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Top 5 Most Recently Viewed Articles
Upcoming Conference Call for VitalHub: Key Details Inside
VitalHub Sets the Stage for Q4 2024 Financial Results VitalHub Corp. (TSX: VHI) (OTCQX: VHIBF) is gearing up to share its financial results for the fourth quarter of 2024, which culminated on December 31. This release is slated for after the market closes on March 27. The excitement surrounding the company's performance and future prospects will take center stage in a...
Continue Reading
Main Street Capital's Strong Q4 Performance Reflects Growth
Main Street Capital's Impressive Q4 Results Main Street Capital Corporation (NYSE: MAIN), a key player in the investment sector with a market capitalization of $5.2 billion, has recently unveiled its preliminary operating results for the fourth quarter of 2024. The company has displayed remarkable performance, boasting an estimated return on equity exceeding 25%. This...
Continue Reading
UNFINISH Unveils Captivating Halloween EDM Album Experience
UNFINISH Releases a Captivating Halloween EDM Album In an exciting turn within the electronic music landscape, UNFINISH has unveiled his latest creation: an album aptly titled HALLOWEEN. This cinematic collection promises to elevate Halloween playlists around the globe, merging an eclectic mix of cyberpunk beats with dramatic emotional narratives. About the Artist Behind...
Continue Reading
Levi Strauss & Co.'s Financial Resilience Amid Market Challenges
Levi Strauss & Co. Shows Financial Strength Recently, BofA Securities reaffirmed a Neutral rating for Levi Strauss & Co. (NYSE: LEVI), highlighting the company's stable price target of $22.00. This rating followed the impressive announcement of Levi's third-quarter adjusted earnings per share (EPS), which reached $0.33, exceeding analysts' expectations of $0.30. This...
Continue Reading
Alamo Group Inc. Announces Leadership Transition Plan
Alamo Group Inc. Announces Leadership Transition Plan Alamo Group Inc. (NYSE: ALG) has recently shared significant news regarding its future leadership. The announcement involves the planned retirement of Jeff Leonard, the Company's President and CEO, who informed the Board of Directors about his intention to retire by mid-year 2025, conditional on the appointment of a...
Continue Reading